Critical need for pharmacologic treatment options in NAFLD: A pediatric perspective

Nonalcoholic fatty liver disease (NAFLD) affects up to 70% of children with obesity and has become the number one etiology for liver transplant in the United States. Early, effective intervention is critical to prevent disease progression into adulthood. Yet, it is seldom achieved through lifestyle...

Descripción completa

Detalles Bibliográficos
Autores principales: Friesen, Chance S., Chan, Sherwin S., Wagner, Jonathan B., Hosey‐Cojocari, Chelsea, Csanaky, Iván L., Shakhnovich, Valentina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212707/
https://www.ncbi.nlm.nih.gov/pubmed/33476465
http://dx.doi.org/10.1111/cts.12952
Descripción
Sumario:Nonalcoholic fatty liver disease (NAFLD) affects up to 70% of children with obesity and has become the number one etiology for liver transplant in the United States. Early, effective intervention is critical to prevent disease progression into adulthood. Yet, it is seldom achieved through lifestyle modification alone. Thus, children must be included in NAFLD pharmacology trials, which, to date, continue to focus primarily on adult populations. This commentary serves as a call to action.

Ejemplares similares